Patent application

Revenue Opportunities Are Missed When The C-suite Doesn't Pay Attention, Says New Clarivate Report

Retrieved on: 
Thursday, February 18, 2021

Two thirds of respondents (66%) said they experienced an increase in applications for image marks over the last 12 months.

Key Points: 
  • Two thirds of respondents (66%) said they experienced an increase in applications for image marks over the last 12 months.
  • Despite the hit to the global economy inflicted by the pandemic in 2020, the volume of new trademark filings rose last year.
  • Only half of all trademark professionals noted that advances in technology will make trademark research and protection more effective.
  • We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise.

United Health Products Obtains International Patent Protection Measures for HemoStyp® Hydrocolloid

Retrieved on: 
Wednesday, February 17, 2021

United Health Products, Inc. (OTC: UEEC), (UHP or the Company), developer of HemoStyp, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced the publication under the Patent Cooperation Treaty of its international patent application relating to any hydrocolloid format of HemoStyp.

Key Points: 
  • United Health Products, Inc. (OTC: UEEC), (UHP or the Company), developer of HemoStyp, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced the publication under the Patent Cooperation Treaty of its international patent application relating to any hydrocolloid format of HemoStyp.
  • The Patent Cooperation Treaty (PCT) is an international patent law treaty which provides a unified procedure for filing a patent application in most foreign countries.
  • The Company previously filed provisional patent applications for its HemoStyp gauze and the hydrocolloid process in July 2020 and 2019, respectively.
  • About United Health Products --UHP develops patented wound care technologies; manufactures and markets hemostatic products for the healthcare and wound care sectors.

Palatin Technologies Announces Filing of International Patent Application Claiming PL9643

Retrieved on: 
Wednesday, February 10, 2021

Palatin recently reported positive results in its Phase 2 study of PL9643 for the treatment of Dry Eye Disease (DED).

Key Points: 
  • Palatin recently reported positive results in its Phase 2 study of PL9643 for the treatment of Dry Eye Disease (DED).
  • A Phase 2/3 clinical trial with PL9643 for the treatment of DED is currently planned for mid-2021.
  • The PCT application for PL9643 establishes the base for the presumptive patent term, and if a patent is granted which claims priority to this application, could provide patent protection for PL9643, and any product in which PL9643 is the active pharmaceutical ingredient, out to 2041, excluding any additional term for patent adjustment or patent term extension.
  • We anticipate filing patent applications in the United States, Europe and a number of additional regions and countries throughout the world.

Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds

Retrieved on: 
Friday, February 5, 2021

The applications include both novel prodrug and deuterated derivatives of psilocybin, which could be candidates for the expedited 505(b)2 approval pathway, as well as potential novel sidechain-restricted psilocybin-inspired psychedelics.

Key Points: 
  • The applications include both novel prodrug and deuterated derivatives of psilocybin, which could be candidates for the expedited 505(b)2 approval pathway, as well as potential novel sidechain-restricted psilocybin-inspired psychedelics.
  • The elegant design of these compounds has drawn on multiple decades of drug design, medicinal chemistry and drug development by the Mindset scientific team.
  • Both the USPTO and PCT patent applications claim priority dates of the Company's previously filed USPTO provisional applications, which were filed on February 4, 2020.
  • The compounds covered under these 2 patent applications are currently undergoing in vivo screening.

Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease

Retrieved on: 
Thursday, February 4, 2021

62/899,899 and entitled, Druggable Targets to Treat Retinal Degeneration filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.

Key Points: 
  • 62/899,899 and entitled, Druggable Targets to Treat Retinal Degeneration filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.
  • : PCT/US2020/050540 and entitled, Druggable Targets to Treat Retinal Degeneration filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications.
  • As stated above, we believe our Metformin reformulation may show efficacy in treating a wide range of RD diseases that cause vision loss.
  • Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease

Retrieved on: 
Thursday, February 4, 2021

62/899,899 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.

Key Points: 
  • 62/899,899 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.
  • : PCT/US2020/050540 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications.
  • The territory for the exclusive license is worldwide.
  • As stated above, we believe our Metformin reformulation may show efficacy in treating a wide range of RD diseases that cause vision loss.

PolarityTE Receives Allowance for Additional U.S. Patent

Retrieved on: 
Wednesday, February 3, 2021

PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S.

Key Points: 
  • PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S.
  • This is the Companys second patent allowance in the United States.
  • The Company continues to pursue additional patent applications in the United States and abroad related to its regenerative technologies, including SkinTE.
  • POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005922/en/

Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets

Retrieved on: 
Monday, February 1, 2021

CA 3050150 to Canntab, related toits proprietary cannabidiol formulations with a priority date of January 23, 2017.

Key Points: 
  • CA 3050150 to Canntab, related toits proprietary cannabidiol formulations with a priority date of January 23, 2017.
  • The Company now has patent protection in Canada and the USA providing an international scope to the Company's expanding portfolio of issued patents."
  • Canntab has filed more than a dozen patent applications in the United States and Canada for which two have now been granted or allowed.
  • On September 21, 2020 Canntab had announced that pursuant to a filing made inMarch 2017, the U.S. Patent and Trademark Office (USPTO) had issued U.S. Patent No.

Intellectual Property / Tech Law Firm Reaches #13 on Top Patent Firms List in Biotechnology & Organics Field

Retrieved on: 
Friday, January 29, 2021

Technology center 1600 at the US Patent Office (USPTO) specializes in the examination of U.S. patent applications in the areas of biotechnology and organic chemistry.

Key Points: 
  • Technology center 1600 at the US Patent Office (USPTO) specializes in the examination of U.S. patent applications in the areas of biotechnology and organic chemistry.
  • "Our continued success reflects the hard work and dedication of our attorneys and staff.
  • It is an honor to once again top Harrity's Top Patent Firms List," said Susan McBee, Managing Partner.
  • MMV was founded in 2016 and is a boutique patent law firm that strives to provide more efficient and streamlined services to clients at a reasonable cost.

Eco Innovation Announces SEC Declaration of Effectiveness of S-1 Filing for $1.5M Direct Offering

Retrieved on: 
Tuesday, January 19, 2021

The registration statement relates to the Companys Primary Direct Offering, which involves the sale of 25,000,000 shares for an aggregate of $1,500,000 in gross proceeds at an offering price of $0.06 per share.

Key Points: 
  • The registration statement relates to the Companys Primary Direct Offering, which involves the sale of 25,000,000 shares for an aggregate of $1,500,000 in gross proceeds at an offering price of $0.06 per share.
  • Proceeds will be utilized for key investments in Research & Development, Manufacturing, Patent Filings & Patent development, Marketing, Salaries & Consulting fees, and General and Administrative expenses.
  • FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S.
  • Any forward-looking information provided in this release should be considered with these factors in mind.